AMGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 310.2 USD | -0.87% |
|
-0.37% | +7.68% |
| May. 09 | ANALYST RECOMMENDATIONS : UBER, Luluemon, Airbnb, Progressive... |  |
| May. 09 | Redburn Atlantic Adjusts Price Target on Amgen to $180 From $170 | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 33.02B | Sales 2025 * | 34B | Capitalization | 166B |
|---|---|---|---|---|---|
| Net income 2024 * | 4.18B | Net income 2025 * | 6.7B | EV / Sales 2024 * | 6.51 x |
| Net Debt 2024 * | 48.47B | Net Debt 2025 * | 43.51B | EV / Sales 2025 * | 6.17 x |
| P/E ratio 2024 * |
39.7
x | P/E ratio 2025 * |
24.4
x | Employees | 26,700 |
| Yield 2024 * |
2.99% | Yield 2025 * |
3.22% | Free-Float | 99.75% |
More Fundamentals
* Assessed data
More news
Latest transcript on Amgen Inc.
More recommendations
More press releases
More news
| 1 day | +1.52% | ||
| 1 week | -0.37% | ||
| Current month | +13.22% | ||
| 1 month | +16.40% | ||
| 3 months | +6.54% | ||
| 6 months | +16.03% | ||
| Current year | +7.68% |
1 week
297.52
314.89
1 month
260.68322.60
Current year
260.68329.72
1 year
211.71329.72
3 years
198.64329.72
5 years
166.30329.72
10 years
109.92329.72
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 61 | 06-05-31 |
Peter Griffith
DFI | Director of Finance/CFO | 65 | 19-10-22 |
James Bradner
CTO | Chief Tech/Sci/R&D Officer | 52 | Dec. 17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Charles Holley
BRD | Director/Board Member | 67 | 17-02-02 |
Ellen Kullman
BRD | Director/Board Member | 68 | 16-10-13 |
Robert Williams
BRD | Director/Board Member | 75 | 14-10-16 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.84% | 0 M€ | 0.00% | - | |
| 7.63% | 0 M€ | 0.00% | - | |
| 5.08% | 0 M€ | +15.26% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 310.2 | -0.87% | 2,611,880 |
| 24-05-09 | 312.9 | +1.81% | 2,921,337 |
| 24-05-08 | 307.3 | +2.33% | 2,859,572 |
| 24-05-07 | 300.3 | +0.27% | 2,452,223 |
| 24-05-06 | 299.5 | -3.79% | 4,717,645 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotes
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
310.2
USD
Average target price
313.8
USD
Spread / Average Target
+1.18%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.68% | 166B | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| -2.71% | 159B |
- Stock Market
- Equities
- AMGN Stock